YAP/TEAD4‐induced KIF4A contributes to the progression and worse prognosis of esophageal squamous cell carcinoma. Issue 7 (18th May 2021)

• Record Type: Journal Article
• Authors: Li, Ya; Zhu, Xiangzhan; Yang, Minglei; Wang, Yingying; Li, Jianhui; Fang, Jiarui; Guo, Wenna; Ma, Shanshan; Guan, Fangxia
• Is Part Of: Molecular carcinogenesis. Volume 60:Issue 7(2021)
• Page Start: 440
• Page End: 454
• Publication Date: 2021-05-18
• Subjects: esophageal squamous cell carcinoma -- KIF4A -- proliferation -- TEAD4 -- YAP; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.23303
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract: Aberrant expression of kinesin family member 4A (KIF4A), which is associated with tumor progression, has been reported in several types of cancer. However, its expression and the underlying molecular mechanisms regulating the transcription of KIF4A in esophageal squamous cell carcinoma (ESCC) remain largely unclear. Here, we found that high KIF4A expression was positively correlated with tumor stage and poor prognosis in ESCC patients. KIF4A silencing significantly inhibited the growth and migration of ESCC cells, arrested cell cycle, and induced apoptosis. Interestingly, KIF4A expression was positively related to the expression of YAP in human ESCC tissues. YAP knockdown or disrupting YAP/TEAD4 interaction by verteporfin repressed KIF4A expression. Also, KIF4A knockdown significantly inhibited the cell growth induced by YAP overexpression. Mechanistically, YAP activated KIF4A transcriptional expression by TEAD4‐mediated direct binding to KIF4A promoter. Finally, KIF4A knockdown and verteporfin treatment synergistically inhibited tumor growth in xenograft models. Together, these results indicated that KIF4A, a novel target gene of YAP/TEAD4, may be a progression and prognostic biomarker of ESCC. Targeting drugs for KIF4A combined with YAP inhibitor may be a novel therapeutic strategy for ESCC.